Broxmeyer Hal E
Department of Microbiology and Immunology, and Walther Oncology Center, Indiana University School of Medicine, 950 West Walnut Street, Indianapolis, IN 46202, USA.
Curr Opin Hematol. 2008 Jan;15(1):49-58. doi: 10.1097/MOH.0b013e3282f29012.
Understanding the regulation of hematopoiesis is important for enhanced efficacy of hematopoietic stem and progenitor cell transplantation. Chemokines influence migration, survival, and other actions of hematopoietic stem and progenitor cells. This article summarizes recent progress in understanding the production and actions of chemokines and chemokine receptors, with an emphasis on the SDF-1/CXCL12-CXCR4 axis.
The literature from 2006 to the present is replete with information on SDF-1/CXCL12 activity, including induced intracellular signaling in hematopoietic progenitor cells, lymphocytes, other innate immune cells, breast cancer, and other tumor cells, and on production of SDF-1/CXCL12, and CXCR4, as well as on actions/production of other chemokines. Studies describing these intense research areas are discussed.
Chemokine-chemokine receptor interactions are important to hematopoiesis and immune cell function, two highly interactive processes. Recent studies have clarified the role of chemokines and their receptors in regulating hematopoiesis, and agents modulating chemokines are being evaluated in preclinical and clinical studies. Examples of such efforts include inhibition of CD26 for enhanced homing and engraftment of hematopoietic stem and progenitor cells, and the use of the SDF-1/CXCL12-CXCR4 antagonist, AMD3100 for mobilization of hematopoietic stem and progenitor cells and their use for stem cell transplantation.
了解造血作用的调节对于提高造血干细胞和祖细胞移植的疗效至关重要。趋化因子会影响造血干细胞和祖细胞的迁移、存活及其他活动。本文总结了在理解趋化因子和趋化因子受体的产生及作用方面的最新进展,重点是SDF-1/CXCL12-CXCR4轴。
2006年至今的文献中充斥着关于SDF-1/CXCL12活性的信息,包括其在造血祖细胞、淋巴细胞、其他固有免疫细胞、乳腺癌及其他肿瘤细胞中诱导的细胞内信号传导,以及SDF-1/CXCL12、CXCR4的产生,还有其他趋化因子的作用/产生情况。本文讨论了描述这些热门研究领域的相关研究。
趋化因子-趋化因子受体相互作用对于造血作用和免疫细胞功能这两个高度相互作用的过程非常重要。最近的研究阐明了趋化因子及其受体在调节造血作用中的作用,并且正在临床前和临床研究中评估调节趋化因子的药物。此类研究工作的实例包括抑制CD26以增强造血干细胞和祖细胞的归巢及植入,以及使用SDF-1/CXCL12-CXCR4拮抗剂AMD3100来动员造血干细胞和祖细胞并将其用于干细胞移植。